To mitigate potential infection-related adverse effects after using these novel medications, several guidelines and health authorities advise thorough monitoring for latent and active TB, HBV, human immunodeficiency virus (HIV), and VZV before initiating anti-TNFα biologics treatment [9-11]. The gene discussed is TNF; the disease is tuberculosis.